Advertisement
| cancer of the prostate risk assessment: Prostate Cancer Prevention Jack Cuzick, Mangesh A. Thorat, 2014-02-15 Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers. |
| cancer of the prostate risk assessment: Urological Pathology Mahul B. Amin, John Eble, David Grignon, John Srigley, 2013-11-14 Knowledge in the field of urologic pathology is growing at an explosive pace. Today’s pathologists, specialists, and residents require a comprehensive and authoritative text that examines the full range of urological diseases and their diagnosis. Written by recognized leaders and educators in the field, the text provides readers with a detailed understanding of all diagnostic aspects of urological disease. Inside this unique resource, readers will explore a broad spectrum of practical information—including etiology, diagnostic criteria, molecular markers, differential diagnosis, ancillary tests, and clinical management. This is sure to be the new definitive text for urological pathology! |
| cancer of the prostate risk assessment: Adenocarcinoma of the Prostate Andrew W. Bruce, John Trachtenberg, 2012-12-06 Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book. |
| cancer of the prostate risk assessment: Cancer-Associated Thrombosis Alok A. Khorana, Charles W. Francis, 2007-09-26 Showcasing the expertise of top-tier specialists who contributed to the newly released guidelines for the care of thrombosis in cancer patients, this exciting guide was written and edited by members of the American Society of Clinical Oncology panel, (ASCO), on the prevention and treatment of cancer-associated thrombosis, among others, and provides |
| cancer of the prostate risk assessment: The Great Prostate Hoax Richard J. Ablin, Ronald Piana, 2014-03-04 Reveals how fear-based and inaccurate testing is resulting in unnecessary high-risk surgeries, arguing that the PSA test was never intended for prostate cancer screening. |
| cancer of the prostate risk assessment: Radical Prostatectomy James A. Eastham, Edward M. Schaeffer, 2013-11-13 Radical Prostatectomy: Surgical Perspectives provides surgeons with a comprehensive overview of the anatomical approach to radical prostatectomy, whether done through an open (retropubic) or robotic-assisted laparoscopic approach. All chapters are structured to provide a step-by-step approach to the most technically demanding and most common oncologic procedure in urology surgery. The book includes highly practical presentations of typical surgical patients seen in the clinical practice of urology and relies heavily on illustrations and intraoperative photographs to clearly complement the text. In addition, the book includes a detailed description of the management of uncommon but potentially serious intraoperative complications, including major vascular injury, ureteral transaction, and rectotomy. Written by authors from a variety of integrated disciplines, including anesthesia, cardiology, and nursing Radical Prostatectomy: Surgical Perspectives is a unique and valuable resource in the field of urology both for those currently in training and for those already in surgical practices. |
| cancer of the prostate risk assessment: Prostate Cancer Philip Kantoff, Peter R. Carroll, Anthony V. D'Amico, 2002-01 This volume is the first interdisciplinary medical text on prostate cancer. More than 50 chapters cover all aspects of diagnosis and screening and all forms of accepted treatments of the prostate, with emphasis on the retention of sexual and physiological function. Highlights of the book include the most exhaustive coverage currently available of advanced androgen-sensitive and androgen-refractory disease. An introductory chapter discusses the impact of advances in genetic understanding of prostate cancer on clinical practice. A Brandon-Hill recommended title. |
| cancer of the prostate risk assessment: Reducing Environmental Cancer Risk Suzanne H. Reuben, 2010-10 Though overall cancer incidence and mortality have continued to decline in recent years, cancer continues to devastate the lives of far too many Americans. In 2009 alone, 1.5 million American men, women, and children were diagnosed with cancer, and 562,000 died from the disease. There is a growing body of evidence linking environmental exposures to cancer. The Pres. Cancer Panel dedicated its 2008¿2009 activities to examining the impact of environmental factors on cancer risk. The Panel considered industrial, occupational, and agricultural exposures as well as exposures related to medical practice, military activities, modern lifestyles, and natural sources. This report presents the Panel¿s recommend. to mitigate or eliminate these barriers. Illus. |
| cancer of the prostate risk assessment: Campbell Walsh Wein Urology Alan W. Partin, Craig A. Peters, Louis R. Kavoussi, Alan J. Wein, Roger R. Dmochowski, 2020-03-02 From the basic science underpinnings to the most recent developments in medical and surgical care, Campbell-Walsh-Wein Urology offers a depth and breadth of coverage you won't find in any other urology reference. Now in three manageable volumes, the revised 12th Edition is a must-have text for students, residents, and seasoned practitioners, with authoritative, up-to-date content in an intuitively organized, easy-to-read format featuring key points, quick-reference tables, and handy algorithms throughout. Features shorter, more practical chapters that help you find key information quickly. Includes new chapters on Urinary Tract Imaging: Basic Principles of Nuclear Medicine · Ethics and Informed Consent · Incisions and Access · Complications of Urologic Surgery · Urologic Considerations in Pregnancy · Intraoperative Consultation · Special Urologic Considerations in Transgender Individuals · and more. Covers hot topics such as minimally invasive and robotic surgery; advancements in urologic oncology, including innovative therapeutics for personalized medicine; new approaches to male infertility; technological advances for the treatment of stones; and advances in imaging modalities. Incorporates current AUA/EAU guidelines in each chapter as appropriate Updates all chapters with new content, new advances, and current references and best practices. Extensively updated chapters include Urological Immunotherapy, Minimally Invasive Urinary Diversion, and Updated Focal Therapy for Prostate Cancer. Features more than 175 video clips, including all-new videos on perineal ultrasound, abdominoplasty in prune belly syndrome, partial penectomy, low dose rate brachytherapy, and many more. Written and edited by key opinion leaders, reflecting essential changes and controversies in the field. Expert ConsultT eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, and references from the book on a variety of devices. |
| cancer of the prostate risk assessment: Molecular Biology of Prostate Cancer Manfred Wirth, J. E. Altwein, B. Schmitz-Dräger, S. Kuptz, 2013-05-22 |
| cancer of the prostate risk assessment: Stereotactic Body Radiation Therapy Simon S. Lo, Bin S. Teh, Jiade J. Lu, Tracey E. Schefter, 2012-08-28 Stereotactic body radiation therapy (SBRT) has emerged as an important innovative treatment for various primary and metastatic cancers. This book provides a comprehensive and up-to-date account of the physical/technological, biological, and clinical aspects of SBRT. It will serve as a detailed resource for this rapidly developing treatment modality. The organ sites covered include lung, liver, spine, pancreas, prostate, adrenal, head and neck, and female reproductive tract. Retrospective studies and prospective clinical trials on SBRT for various organ sites from around the world are examined, and toxicities and normal tissue constraints are discussed. This book features unique insights from world-renowned experts in SBRT from North America, Asia, and Europe. It will be necessary reading for radiation oncologists, radiation oncology residents and fellows, medical physicists, medical physics residents, medical oncologists, surgical oncologists, and cancer scientists. |
| cancer of the prostate risk assessment: High-Risk Cutaneous Squamous Cell Carcinoma Chrysalyne D. Schmults, 2016-04-29 This book is a cutting-edge resource that provides clinicians with the up-to-date practical knowledge required in order to manage SCC patients optimally. It summarizes newly available information relating to the definition of high-risk SCC, its pathophysiologic underpinnings, and its management. New prognostic information and staging systems are summarized that enable high-risk tumors to be defined more precisely than ever before. Many helpful tips are provided on the practical management of challenging cases, including multiple tumors/field cancerization, high-risk tumors, nodal metastases, and unresectable disease. The authors are all acknowledged experts in the emerging field of high-risk and advanced SCC. |
| cancer of the prostate risk assessment: Health Risks from Exposure to Low Levels of Ionizing Radiation Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Research Council, 2006-03-23 This book is the seventh in a series of titles from the National Research Council that addresses the effects of exposure to low dose LET (Linear Energy Transfer) ionizing radiation and human health. Updating information previously presented in the 1990 publication, Health Effects of Exposure to Low Levels of Ionizing Radiation: BEIR V, this book draws upon new data in both epidemiologic and experimental research. Ionizing radiation arises from both natural and man-made sources and at very high doses can produce damaging effects in human tissue that can be evident within days after exposure. However, it is the low-dose exposures that are the focus of this book. So-called “late” effects, such as cancer, are produced many years after the initial exposure. This book is among the first of its kind to include detailed risk estimates for cancer incidence in addition to cancer mortality. BEIR VII offers a full review of the available biological, biophysical, and epidemiological literature since the last BEIR report on the subject and develops the most up-to-date and comprehensive risk estimates for cancer and other health effects from exposure to low-level ionizing radiation. |
| cancer of the prostate risk assessment: Salvage Therapy for Prostate Cancer Sanchia S. Goonewardene, Raj Persad, Karen Ventii, David Albala, Declan Cahill, 2020-11-23 This book comprehensively covers application of salvage therapy in reccurrent prostate cancer. Chapters focus on specific issues associated with a range of surgical and oncological management techniques and strategies including hormone therapy, lymphnode dissection, robotic prostatectomy and salvage reirradiation after locoregional failure. Learning objectives, and definitions of keywords are provided to aid the reader develop a thorough understanding of the topic and reinforce the key points covered in each chapter. Salvage Therapy for Prostate Cancer provides a detailed practically applicable guide on how salvage therapy can be utilised in the treatment of prostate cancer. It represents a valuable resource for trainee and practicing urologists, oncologists, and specialist nurses. |
| cancer of the prostate risk assessment: Urologic Pathology Myron P. Tannenbaum, 1977 |
| cancer of the prostate risk assessment: Assessing Genetic Risks Institute of Medicine, Committee on Assessing Genetic Risks, 1994-01-01 Raising hopes for disease treatment and prevention, but also the specter of discrimination and designer genes, genetic testing is potentially one of the most socially explosive developments of our time. This book presents a current assessment of this rapidly evolving field, offering principles for actions and research and recommendations on key issues in genetic testing and screening. Advantages of early genetic knowledge are balanced with issues associated with such knowledge: availability of treatment, privacy and discrimination, personal decision-making, public health objectives, cost, and more. Among the important issues covered: Quality control in genetic testing. Appropriate roles for public agencies, private health practitioners, and laboratories. Value-neutral education and counseling for persons considering testing. Use of test results in insurance, employment, and other settings. |
| cancer of the prostate risk assessment: Risk Assessment and Management in Cancer Genetics Fiona Lalloo, 2005-09-29 This comprehensive text will help the non-specialist undertake cancer risk assessment in the context of a family history, which also provides the foundation for cancer genetics for the specialist. |
| cancer of the prostate risk assessment: The Gleason Grading System Epstein, 2013 The Gleason system is the most important prognostic marker of prostate cancer that is critical to patient management and drives therapies across all disciplines dealing with prostate cancer. In addition to an extensive number of photographs, this book discusses in detail clinically related issues that are crucial for the urologist, radiotherapist, and oncologists to know, such as predicting upgrading and downgrading from needle biopsy to radical prostatectomy, risk of Gleason grading change over time, significance of tertiary grade patterns, and prognosis and implications related to various Gleason scores and different therapies. Images that were particularly difficult for contributing pathologists sent in for consultation are used in addition to classic examples, as these cases are the most informative in showing the difficulties with Gleason grading. |
| cancer of the prostate risk assessment: The Molecular Basis of Cancer John Mendelsohn, Peter M. Howley, Mark A. Israel, Joe W. Gray, Craig B. Thompson, 2008-04-01 Successfully fighting cancer starts with understanding how it begins. This thoroughly revised 3rd Edition explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of cancer. A team of leading experts thoroughly explain the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials and practice. Incorporating cutting-edge advances and the newest research, the book provides thorough descriptions of everything from molecular abnormalities in common cancers to new approaches for cancer therapy. Features sweeping updates throughout, including molecular targets for the development of anti-cancer drugs, gene therapy, and vaccines...keeping you on the cutting edge of your specialty. Offers a new, more user-friendly full-color format so the information that you need is easier to find. Presents abundant figures-all redrawn in full color-illustrating major concepts for easier comprehension. Features numerous descriptions of the latest clinical strategies-helping you to understand and take advantage of today’s state-of-the-art biotechnology advances. |
| cancer of the prostate risk assessment: Gleason Grading of Prostate Cancer Mahul B. Amin, 2004 Featuring more than 300 full-color photomicrographs that represent the entire spectrum of the Gleason grading system, this atlas is the first comprehensive and definitive reference devoted to Gleason grading of prostate cancer. It is written by four eminent authorities in urologic pathology who bring their collective expertise and consensus opinion in Gleason grading. Illustrative case examples from the authors' collections highlight the pitfalls and problems of applying the Gleason grading system to contemporary techniques in pathology. |
| cancer of the prostate risk assessment: Cancer Genetics: A Clinical Approach Xavier Llor, Erin Wysong Hofstatter, 2021-11-19 The ultimate guide to caring for and communicating with patients suffering with hereditary cancer syndromes Providing the essential tools needed to understand clinical cancer genetics, Cancer Genetics: A Clinical Approach builds your mastery of differential diagnosis formulation, all the available genetic testing options at your disposal, interpreting results logically and accurately, and educating patients and their families about effective cancer prevention methods. This unparalleled resource walks you through the process of effectively and thoughtfully counseling patients—from pre-test counseling and relaying test results to navigating the legal implications of hereditary conditions and coping with the resulting psychological challenges. Cancer Genetics: A Clinical Approach is ideal for both specialized cancer genetics clinics or any healthcare professional seeking to improve their skills in identifying patients with possible hereditary cancer syndromes and recognizing which ones should be referred to a high-risk/clinical genetics specialty program. |
| cancer of the prostate risk assessment: AJCC Cancer Staging Manual Frederick L, Greene, David L. Page, Irvin D. Fleming, April G. Fritz, Charles M. Balch, Daniel G. Haller, Monica Morrow, 2013-11-21 The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms. |
| cancer of the prostate risk assessment: Pathology of the Prostate Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi, Maria Rosaria Raspollini, 2017-11-30 A practical approach to pathology of the prostate with integrated algorithms using classic histopathology, representative images and relevant immunohistochemistry. |
| cancer of the prostate risk assessment: Normal Human Aging , 1984 |
| cancer of the prostate risk assessment: Prostatic Ultrasonography Martin I. Resnick, 1990 Focusing on the diagnosis of prostate disorders via ultrasound, this work discusses recent advances and techniques, such as transrectal views. Coverage includes prostate cancer, prostate and ultrasound anatomy, benign hyperplasia, inflammatory disease and calculi and male infertility. |
| cancer of the prostate risk assessment: Digital Breast Tomosynthesis Alberto Tagliafico, Nehmat Houssami, Massimo Calabrese, 2016-05-03 This book provides a comprehensive description of the screening and clinical applications of digital breast tomosynthesis (DBT) and offers straightforward, clear guidance on use of the technique. Informative clinical cases are presented to illustrate how to take advantage of DBT in clinical practice. The importance of DBT as a diagnostic tool for both screening and diagnosis is increasing rapidly. DBT improves upon mammography by depicting breast tissue on a video clip made of cross‐sectional images reconstructed in correspondence with their mammographic planes of acquisition. DBT results in markedly reduced summation of overlapping breast tissue and offers the potential to improve mammographic breast cancer surveillance and diagnosis. This book will be an excellent practical teaching guide for beginners and a useful reference for more experienced radiologists. |
| cancer of the prostate risk assessment: Prostate Cancer Diagnosis J. Stephen Jones, 2012-11-14 Based on the highly successful first edition of Prostate Biopsy: Indications, Techniques, and Complications, this new volume presents new concepts that have emerged in answer to current questions from its audience. Many new perspectives and technologies are presented, many from the authors’ internationally recognized work on the topic. Substantial developments in techniques and complications are explored in detail. The chapter authors comprise a complete spectrum of specialists in their respective subject areas. All authors are internationally accepted as the premier authorities on their chosen topics. Prostate Cancer Diagnosis: PSA, Biopsy, and Beyond presents new data on the controversial issue of PSA screening and thresholds as indication to perform biopsy. Office based transrectal saturation biopsy is covered in detail. Other topics explored include template guided biopsy and image-guided biopsy as well as a completely new paradigm for prevention of complications. Prostate Cancer Diagnosis: PSA, Biopsy, and Beyond will be of great value and utility to all practicing urologists. |
| cancer of the prostate risk assessment: Meta-analysis by the Confidence Profile Method David M. Eddy, 1992 |
| cancer of the prostate risk assessment: Cancer Clinical Trials Tomasz M. Beer, Larry Axmaker, 2012 A readable guide for anyone who is considering therapeutic options in addition to standard cancer therapy. The book seeks to share knowledge about cancer clinical trials with people living with cancer, their families and loved ones. |
| cancer of the prostate risk assessment: Psychosocial Genetic Counseling Jon Weil, 2000-09-07 Psychosocial issues are integral to all genetic counseling interactions. They include counselees' beliefs about the cause of birth defects and genetic disorders, the cognitive procession of medical information and risk figures, emotions such as anxiety and guilt, and the complex process of decision making. Drawing on direct clinical experience and the growing body of relevant literature, Psychosocial Genetic Counseling provides a comprehensive, integrated approach to understanding these issues and their applications to genetic counseling. The book combines theoretical and practical approaches, including many clinical vignettes and examples of dialogue. It is written in an engaging style that conveys the emotional immediacy of genetic counseling. The emotional and social effects of genetic disorders are discussed with reference to the individual and to couple, family, and social interactions. Counseling techniques and the agenda of the genetic counseling session are then addressed in detail. Specialized aspects of prenatal diagnosis counseling, cancer risk counseling, and genetic counseling with children and adolescents are integrated with these general principles. Nondirective counseling and the psychology of risk interpretation and decision making are discussed from theoretical and historical perspectives, leading to recommendations for their application to clinical practice. The influences of ethnocultural history, beliefs and practices, for counselee and counselor, are then discussed as they enter into all aspects of genetic counseling. |
| cancer of the prostate risk assessment: A Guide to Genetic Counseling Wendy R. Uhlmann, Jane L. Schuette, Beverly M. Yashar, 2011-09-20 The first book devoted exclusively to the principles and practice of genetic counseling—now in a new edition First published in 1998, A Guide to Genetic Counseling quickly became a bestselling and widely recognized text, used nationally and internationally in genetic counseling training programs. Now in its eagerly anticipated Second Edition, it provides a thoroughly revised and comprehensive overview of genetic counseling, focusing on the components, theoretical framework, and unique approach to patient care that are the basis of this profession. The book defines the core competencies and covers the genetic counseling process from case initiation to completion—in addition to addressing global professional issues—with an emphasis on describing fundamental principles and practices. Chapters are written by leaders in the field of genetic counseling and are organized to facilitate academic instruction and skill attainment. They provide the most up-to-date coverage of: The history and practice of genetic counseling Family history Interviewing Case preparation and management Psychosocial counseling Patient education Risk communication and decision-making Medical genetics evaluation Understanding genetic testing Medical documentation Multicultural counseling Ethical and legal issues Student supervision Genetic counseling research Professional development Genetics education and outreach Evolving roles and expanding opportunities Case examples A Guide to Genetic Counseling, Second Edition belongs on the syllabi of all medical and human genetics and genetic counseling training programs. It is an indispensable reference for both students and healthcare professionals working with patients who have or are at risk for genetic conditions. |
| cancer of the prostate risk assessment: Prostate Cancer, An Issue of Urologic Clinics Marc A. Bjurlin, Samir S. Taneja, 2017-11-06 Dr. Samir Taneja, Consulting Editor, is stepping into the Guest Editor role for this issue of Urologic Clinics devoted to Prostate Cancer. He has assembled top experts to address the latest advances in the diagnosis and treatment of prostate cancer. Articles are devoted to the following topics: Whom to Biopsy: Pre-Diagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators; How to Biopsy: Transperineal vs. Tranrectal, Saturation vs. Targeted: What’s the Evidence; Pre-Diagnostic Risk and Assessment with Imaging and Image-guided Biopsy; Whom to treat: Post-Diagnostic Risk Assessment with Gleason score, Risk Models, and Genomic Classifier; Strategies for Staging and Utilization of Imaging; Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes; Focal Ablation of Early Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome; Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-based Approach; How to Radiate the Prostate: Hypofractionation, Sterotactic Body Radiation Therapy, and Conventional Intensity-Modulated Radiotherapy; Managing Relapse after Surgical Therapy: Adjuvant vs. Salvage Therapy; Newly diagnosed Metastatic Prostate Cancer – Has the Paradigm Changed; Role of Local therapy in Oligometastatic Prostate Cancer: Should we Expect Cure; Approaching the High-Risk Patient; and Castration-Resistant Prostate Cancer: An Algorithmic Approach. Readers will come away with state-of-the-art information on strategies for diagnosing, treating, and managing prostate cancer. |
| cancer of the prostate risk assessment: The Prostate Cancer Dilemma Nelson N. Stone, E. David Crawford, 2015-10-19 This text provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative and in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs is addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of this new technology in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a very useful resource for physicians and researchers dealing with, and interested in this challenging malignancy. Chapters are written by experts in their fields and include the most up to date scientific and clinical information as well as links to procedural video content. |
| cancer of the prostate risk assessment: Toxicology and Risk Assessment Anna M. Fan, George Alexeeff, Elaine Khan, 2015-03-04 The presence of chemicals in our environment is a subject of intense interest owing to the many potential adverse health effects to humans following exposure to these chemicals. The principles and practices of risk assessment are used to assess the associated health risks to provide a scientific and health basis for guidance or regulatory standards |
| cancer of the prostate risk assessment: Risk Assessment Valentina Svalova, 2018-02-28 Risk assessment is one of the main parts of complex systematic research of natural and man-made hazards and risks together with the concepts of risk analysis, risk management, acceptable risk, and risk reduction. It is considered as the process of making a recommendation on whether existing risks are acceptable and present risk control measures are adequate, and if they are not, whether alternative risk control measures are justified or will be implemented. Risk assessment incorporates the risk analysis and risk evaluation phases. Risk management is considered as the complete process of risk assessment, risk control, and risk reduction. The book reflects on the state-of-the-art problems and addresses the risk assessment to establish the criteria for ranking risk posed by different types of natural or man-made hazards and disasters, to quantify the impact that hazardous event or process has on population and structures, and to enhance the strategies for risk reduction and avoiding. |
| cancer of the prostate risk assessment: Active Surveillance for Localized Prostate Cancer Laurence Klotz, 2018-08-26 This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. |
| cancer of the prostate risk assessment: Multigene Panels in Prostate Cancer Risk Assessment U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality, 2013-03-22 Prostate cancer is the fifth most common malignancy in the world, with a large variation in incidence rates. In 2010, it was estimated that almost a quarter of a million new cases were diagnosed in North America, and more than 36,000 men died from the disease. Apart from age, ethnic group, and family history, the risk factors associated with prostate cancer are unclear, making primary prevention difficult. Striking differences in incidence have been observed for different ethnic groups and populations. A high incidence has been observed in populations of African descent in several countries. First-degree relatives of men with prostate cancer have a two- to threefold increased risk for developing the disease, and its estimated heritability is high. Some patterns of familial aggregation have been observed that are consistent with an autosomal dominant mode of inheritance of a susceptibility gene, but this accounts for no more than 15 percent of cases. Prostate cancer is currently considered to be a complex, multifactorial disease with the vast majority of familial clustering attributed to the interaction of multiple shared moderate to low penetrance susceptibility genes and shared environmental factors within these families. Many epidemiological studies have suggested a wide range of other risk factors for prostate cancer, but these have not been confirmed in controlled trials. The natural history of prostate cancer is highly variable. In a large proportion of men, the disease is indolent, and it is difficult to predict which tumors will be aggressive. African-American men have a poorer prognosis than other groups, independent of comorbidity or access to health services. The value of aggressive management for localized prostate cancer is also debated, and only a small proportion of men with early stage prostate cancer die from the disease within 10 to 15 years of diagnosis. Prostate-specific antigen (PSA) was approved by the U.S. Food and Drug Administration in 1986 for monitoring progression in patients with prostate cancer, and later approved for the detection of the disease in symptomatic men (but not for screening asymptomatic men). A meta-analysis of seven randomized controlled trials of screening using PSA testing alone, or in combination with digital rectal examination, suggested no evidence of benefit in reducing mortality, and some evidence of harms from overdiagnosis. Amidst substantial debate, the argument has been made for developing more accurate screening tests, including possible genetic markers. Single nucleotide polymorphisms (SNPs) are minute inherited variations in the DNA sequence. SNPs occur about once in every 800 base pairs and are the most common type of genetic variation in humans. Since 2001, there have been about 1,000 published studies reporting associations between prostate cancer, SNPs, and other genetic variants. To date, genome-wide association (GWA) studies have identified replicated associations between prostate cancer and almost 40 specific SNPs. The aim of this review is to assess the evidence on the possible value of SNP panels in the detection of and prediction of risk for prostate cancer, and their value in predicting disease prognosis in affected men. This report addresses the evidence on the validity and utility of using SNP panels in the detection, diagnosis, and clinical management of prostate cancer. The specific Key Questions are: 1. What is the analytic validity of currently available SNP-based panels designed for prostate cancer risk assessment? 2. What is the clinical validity of currently available SNP-based panels designed for prostate cancer risk assessment? 3. What is the clinical utility of currently available SNP-based panels for prostate cancer risk assessment, in terms of the process of care, health outcomes, harms, and economic considerations? |
| cancer of the prostate risk assessment: WHO Classification of Tumours of the Urinary System and Male Genital Organs International Agency for Research on Cancer, 2016-02-02 WHO Classification of Tumours of the Urinary System and Male Genital Organs is the eighth volume in the 4th Edition of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. It contains numerous color photographs, MRIs, ultrasound images, CT scans, charts and references. |
| cancer of the prostate risk assessment: Management of Prostate Cancer Michel Bolla, Hendrik van Poppel, 2012-04-24 This book provides an exhaustive review of the current state of the art in the management of prostate cancer, from screening to treatment. A particular feature is the emphasis placed on the value of a multidisciplinary approach. The opening chapters address basic aspects including epidemiology, biology, and chemoprevention. The role of individual and mass screening is carefully appraised, and diagnosis, clinical work-up, and the role of active surveillance are discussed in detail. Subsequent chapters are devoted to each of the therapies that may be employed, including open and robotic laparoscopic radical prostatectomy, the various forms of radiation therapy, high-intensity focused ultrasound, cryotherapy, hormonal therapy, and targeted therapies and vaccination. Up-to-date data from clinical trials are included. The editors are members of the EORTC who have coordinated phase III EORTC trials and have worldwide reputations. |
| cancer of the prostate risk assessment: Active Surveillance for Localized Prostate Cancer Laurence Klotz, 2012-06-21 Active Surveillance for Localized Prostate Cancer: A New Paradigm for Clinical Management will serve as a useful resource for physicians dealing with, and interested in, this complex and evolving branch of prostate cancer management. The book will also be of interest to scientifically literate patients and their families. The volume provides an introduction to the concept of active surveillance in oncology in general and prostate cancer specifically. The primary focus is to provide a comprehensive guide to the management of patients on surveillance. The volume covers the many complexities and nuances to this approach including, patient selection, risk assessment, how to overcome 'cancer hysteria' when counseling patients, identifying appropriate triggers for intervention, use of PSA kinetics and MR imaging information, technique and frequency of biopsies, secondary prevention interventions, and the relative roles of surveillance and focal therapy. |
¿Qué es el cáncer? - National Cancer Institute
Definición de cáncer, explicación breve de cómo se origina el cáncer en las células del cuerpo, estadísticas básicas de cáncer y enlaces a otros recursos del NCI.
Cancer - Symptoms and causes - Mayo Clinic
Nov 19, 2024 · Causes. Cancer is caused by changes (mutations) to the DNA within cells. The DNA inside a cell is packaged into a large number of individual genes, each of which contains a set of …
Cancer - Wikipedia
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. [2] [7] These contrast with benign tumors, which do not spread. [7]
Cancer: Types, Causes, Treatment, and Prevention - Healthline
Jan 17, 2023 · Cancer is a group of diseases that occur when abnormal cells divide rapidly and spread. Learn the types, causes, treatments, and prevention methods.
Comprehensive Cancer Information - NCI
NCI is the nation’s trusted source for cancer information. We are here for you with information about causes and risk factors, symptoms, how cancer is diagnosed, and treatment options.
Cancer - World Health Organization (WHO)
Feb 3, 2025 · Key facts. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, …
End Cancer As We Know It | American Cancer Society
Dedicated to helping people who face cancer. Learn about cancer research, patient services, early detection, treatment and education at cancer.org.
Cancer - Wiley Online Library
1 day ago · Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Cáncer en español - National Cancer Institute
Las terapias combinadas con la QETA son eficaces para tratar el cáncer de hígado. Se observaron resultados favorables en dos estudios en los que se combinó un procedimiento llamado …
What Is Cancer? | Cancer Basics - American Cancer Society
Cancer is a group of diseases where abnormal cells grow out of control and crowd out normal cells. It affects 1 in 3 people in the United States. Chances are that you or someone you know has been …
¿Qué es el cáncer? - National Cancer Institute
Definición de cáncer, explicación breve de cómo se origina el cáncer en las células del cuerpo, estadísticas básicas de cáncer y enlaces a otros recursos del NCI.
Cancer - Symptoms and causes - Mayo Clinic
Nov 19, 2024 · Causes. Cancer is caused by changes (mutations) to the DNA within cells. The DNA inside a cell is packaged into a large number of individual genes, each of which contains …
Cancer - Wikipedia
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. [2] [7] These contrast with benign tumors, which do not …
Cancer: Types, Causes, Treatment, and Prevention - Healthline
Jan 17, 2023 · Cancer is a group of diseases that occur when abnormal cells divide rapidly and spread. Learn the types, causes, treatments, and prevention methods.
Comprehensive Cancer Information - NCI
NCI is the nation’s trusted source for cancer information. We are here for you with information about causes and risk factors, symptoms, how cancer is diagnosed, and treatment options.
Cancer - World Health Organization (WHO)
Feb 3, 2025 · Key facts. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, …
End Cancer As We Know It | American Cancer Society
Dedicated to helping people who face cancer. Learn about cancer research, patient services, early detection, treatment and education at cancer.org.
Cancer - Wiley Online Library
1 day ago · Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Cáncer en español - National Cancer Institute
Las terapias combinadas con la QETA son eficaces para tratar el cáncer de hígado. Se observaron resultados favorables en dos estudios en los que se combinó un procedimiento …
What Is Cancer? | Cancer Basics - American Cancer Society
Cancer is a group of diseases where abnormal cells grow out of control and crowd out normal cells. It affects 1 in 3 people in the United States. Chances are that you or someone you know …
